Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04228783 · ClinicalTrials.gov registry record · Phase 3
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
A Phase 3 study of Ebola, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 974
- Enrollment target
- 7
- Study locations
NCT04228783: Completed Phase 3 study of Ebola, sponsored by Janssen Vaccines & Prevention B.V..
NCT04228783 is a Phase 3 study of Ebola that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 974 participants. The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04228783, a Phase 3 study of Ebola, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 974 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) including the ebola virus mayinga glycoprotein as Dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.ZEBOV
- BIOLOGICAL MVA-BN-Filo
Study Locations (7)
Alabama
- Coastal Clinical Research, Inc - Mobile
Arizona
- Clinical Research Consortium, an AMR company - Tempe
Kentucky
- Central Kentucky Research Associates, Inc. - Lexington
Missouri
- The Center For Pharmaceutical Research - Kansas City
Nevada
- Clinical Research Consortium, an AMR company - Las Vegas
Tennessee
- AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company - Knoxville
Virginia
- Alliance for Multispeciality Research - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 974 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04228783
The ClinicalTrials.gov registry entry for NCT04228783 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 974 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ebola appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04228783 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, Arizona, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04228783 about?
NCT04228783 is a clinical study titled "A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants". The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic ...
What is the current status of trial NCT04228783?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 974 participants. The study started on 2020-02-18. Estimated completion is 2022-04-25.
What conditions does trial NCT04228783 study?
This clinical trial studies the following conditions: Ebola.
What interventions are being tested in trial NCT04228783?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.ZEBOV (BIOLOGICAL), MVA-BN-Filo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04228783?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04228783 being conducted?
This trial has 7 study locations across Alabama, Arizona, Kentucky, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.